Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production

Cellular Immunology

Volumn 223, Issue 1, 2003, Pages 52-62

  Sun, Dongxu ^a   Fernandes, Gabriel ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Dendritic cells; Immune response; Lovastatin; Statins

Indexed keywords

B7 ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CD11B ANTIGEN; CD16 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL EXTRACT; COMPLEMENTARY DNA; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; MEVINOLIN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL ACTIVITY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE ACTIVATION;

EID: 0043166922     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-8749(03)00148-5     Document Type: Article

References (49)

1. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
2. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 278:1997;313-321.
3. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:2000;1399-1402.
4. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., Cogert G.A.et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333:1995;621-627.
5. Mach B., Steimle V., Martinez-Soria E., Reith W. Regulation of MHC ClassII genes: lessons from a disease. Annual Review of Immunology. 1996;Annual Reviews Inc, Palo Alto, CA.
6. Huhle G., Abletshauser C., Mayer N., Weidinger G., Harenberg J., Heene D.L. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb. Res. 95:1999;229-234.
7. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
8. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:1997;10-16.
9. Jakobisiak M., Bruno S., Skierski J.S., Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA. 88:1991;3628-3632.
10. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods. 223:1999;77-92.
11. Fernandes G., Handwerger B.S., Yunis E.J., Brown D.M. Immune response in the mutant diabetic C57BL/Ks-db+ mouse. Discrepancies between in vitro and in vivo immunological assays. J. Clin. Invest. 61:1978;243-250.
12. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475-1489.
13. Jolly C.A., Muthukumar A., Reddy Avula C.P., Fernandes G. Maintenance of NF-kappaB activation in T-lymphocytes and a naive T-cell population in autoimmune-prone (NZB/NZW)F(1) mice by feeding a food-restricted diet enriched with n-3 fatty acids. Cell Immunol. 213:2001;122-133.
14. Sun D., Muthukumar A.R., Lawrence R.A., Fernandes G. Effects of calorie restriction on polymicrobial peritonitis induced by cecum ligation and puncture in young C57BL/6 mice. Clin. Diag. Lab. Immunol. 8:2001;1003-1011.
15. Guijarro C., Kim Y., Schoonover C.M., Massy Z.A., O'Donnell M.P., Kasiske B.L., Keane W.F., Kashtan C.E. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol. Dial Transplant. 11:1996;990-996.
16. ′ -methylthioadenosine: roles of protein isoprenylation and carboxyl methylation reactions Mol. Cell Biol. 12:1992;103-111.
17. Lanzavecchia A. Identifying strategies for immune intervention. Science. 260:1993;937-944.
18. Feuillard J., Korner M., Israel A., Vassy J., Raphael M. Differential nuclear localization of p50, p52, and RelB proteins in human accessory cells of the immune response in situ. Eur. J. Immunol. 26:1996;2547-2551.
19. Weih F., Carrasco D., Durham S.K., Barton D.S., Rizzo C.A., Ryseck R.P., Lira S.A., Bravo R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell. 80:1995;331-340.
20. Burkly L., Hession C., Ogata L., Reilly C., Marconi L.A., Olson D., Tizard R., Cate R., Lo D. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature. 373:1995;531-536.
21. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1994;1109-1118.
22. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:1995;389-400.
23. De Smedt T., Pajak B., Muraille E., Lespagnard L., Heinen E., De Baetselier P., Urbain J., Leo O., Moser M. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184:1996;1413-1424.
24. Rescigno M., Martino M., Sutherland C.L., Gold M.R., Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188:1998;2175-2180.
25. Ardeshna K.M., Pizzey A.R., Devereux S., Khwaja A. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood. 96:2000;1039-1046.
26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389.
27. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med. 335:1996;1001-1009.
28. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1995;1301-1307.
29. Massy Z.A., Keane W.F., Kasiske B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 347:1996;102-103.
30. Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
31. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., Tyroler H.A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 322:1990;1700-1707.
32. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
33. Folcik V.A., Aamir R., Cathcart M.K. Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler. Thromb. Vasc. Biol. 17:1997;1954-1961.
34. Ferro D., Parrotto S., Basili S., Alessandri C., Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J. Am. Coll. Cardiol. 36:2000;427-431.
35. Terkeltaub R., Solan J., Barry M. Jr., Santoro D., Bokoch G.M. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J. Leukoc. Biol. 55:1994;749-755.
36. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Muller M.R., Husslein P., Kashanipour A., Minar E., Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22:2002;1194-1199.
37. de Bont N., Netea M.G., Rovers C., Smilde T., Demacker P.N., van der Meer J.W., Stalenhoef A.F. LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis. 139:1998;147-152.
38. Fukuo Y., Nagashima M., Soya-Ohmura N., Takagi S., Terashi A., Ikejima T. Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages. Nippon Ika Daigaku Zasshi. 62:1995;386-390.
39. Montero M.T., Hernandez O., Suarez Y., Matilla J., Ferruelo A.J., Martinez-Botas J., Gomez-Coronado D., Lasuncion M.A. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis. 153:2000;303-313.
40. Rasmussen L.M., Hansen P.R., Nabipour M.T., Olesen P., Kristiansen M.T., Ledet T. Diverse effects of inhibition 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J. 360:2001;363-370.
41. Schmidt A., Goepfert C., Feitsma K., Buddecke E. Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF-alpha activated human vascular endothelial cells. Atherosclerosis. 164:2002;57-64.
42. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
43. Stanislaus R., Singh A.K., Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 66:2001;155-162.
44. Fried L.F., Forrest K.Y., Ellis D., Chang Y., Silvers N., Orchard T.J. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J. Diabetes Complications. 15:2001;113-119.
45. Khosla R., Butman A.N., Hammer D.F. Simvastatin-induced lupus erythematosus. South Med. J. 91:1998;873-874.
46. Sweany A.E. Dosing and administration schedule of HMG CoA reductase inhibitors. Heart Dis. Stroke. 2:1993;263.
47. Bannwarth B., Miremont G., Papapietro P.M. Lupuslike syndrome associated with simvastatin. Arch. Intern. Med. 152:1992;1093.
48. Ahmad S. Lovastatin-induced lupus erythematosus. Arch. Intern. Med. 151:1991;1667-1668.
49. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Krobot K., Steinbeck G., Seidel D., Reichart B. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 107:2003;93-97.